News

Head of Corporate Strategy and Development at C4XD, Bhavna Hunjan, spoke to Kevin Grogan at IN VIVO on business development and partnering strategies in drug discovery.

Bhavna Hunjan, Head of Corporate Strategy and Development at C4X Discovery talks about Business Development in a Virtual World.

Wednesday, 22 July 2020 - European Biopharmaceutical Review

In the News The Promise of Drug Discovery

C4XD's CSO, Craig Fox, speaks to European Biopharmaceutical Review on "The Promise of Drug Discovery".

Government’s taskforce to lead UK efforts to deliver a COVID-19 vaccine

5 June 2020 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to confirm that Clive Dix, Chief Executive Officer of C4XD has been appointed a member and Deputy Chair of the Steering Board of the UK Vaccine Taskforce, the group set up by the Government’s Chief Scientific Adviser, Deputy Chief Medical Officer, Business Secretary and Health Secretary to lead UK efforts to find and manufacture a COVID-19 vaccine.

Successfully raises approximately £1.6 million led by Polar Capital

Advancing the next wave of out-licensing opportunities

7 May 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to announce the completion of the Placing announced earlier today.

Advancing the next wave of out-licensing opportunities

7 May 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces a proposed Placing of Placing Shares with existing and new institutional investors to raise a minimum of approximately £1.0 million in aggregate before expenses at the Issue Price of 15 pence per Placing Share.

The criticality of venturing into new drugs has been discussed in the earlier segment, and an encouraging step has been taken in this direction. C4X Discovery (C4XD), a leading UK-based drug discovery company which develops new drug combinations for chronic addiction and cancer is credited to create its own VR tool named, 4Sight...

Clive Dix talks Proactive London's Andrew Scott through its interim results to January 2020.

Dix says its NRF-2 activator programme for sickle cell disease and pulmonary arterial hypertension is progressing and it is down to a short-list of three molecules.